ADMETECH FOUNDATION is a 501(c)(3) non-profit organization leading the battle against prostate cancer through the advancement of patient care, including screening, accurate diagnosis and treatment. Established in 1997, our mission is to end prostate cancer (PC) as a patient care crisis and socioeconomic problem.

OUR FOCUS is on the Manogram® Project, dedicated to the development and implementation of precision diagnostic tools, which are critical for improved prostate cancer care and akin to life-saving mammograms for breast cancer management.

Our groundbreaking awareness, education and advocacy programs expedite advancement and integration of precision, broad-based diagnostics, including but not limited to, biomarkers, genetics, genomics, imaging and proteomics for individualized, precision care.

Our research programs are uniquely focused on facilitated development, standardization, evaluation and clinical implementation of advanced prostate imaging, which will end the era of blind patient care and create the future of precisely-targeted, minimally-invasive diagnosis, biopsies and treatment.

PROBLEM: THE PROSTATE CANCER CRISIS

- Prostate cancer is the most common major malignancy in the US, striking as many as 1 in 9 men.
- Over 2.7 million men live with prostate cancer today.
- Though curable when detected early, prostate cancer remains the second most lethal malignancy in men. An American man dies every 19 minutes.
- Black men are disproportionately affected, with a 2.5 times higher mortality rate.
- While prostate cancer is more prevalent than even breast cancer, public awareness and national research investments are lagging behind. As a result, men do not have accurate diagnostic tools akin to life-saving mammograms.
- The lack of accurate diagnostic tools leads to widespread unnecessary and failed procedures, including biopsies and treatment, decreases quality of life in millions of men and adds billions of dollars to health care costs each year.

SOLUTION: ACCURATE DIAGNOSTIC TOOLS FOR MEN

WHY: Just as mammography, molecular and genetic tests have transformed breast cancer care, accurate diagnostic tools for men will enable:

- Improved early detection of aggressive prostate cancer, critical for saving lives;
- Elimination of unnecessary biopsies for benign or dormant diseases, which are not likely to cause symptoms;
- Replacement of immediate invasive treatment with observation strategies (e.g., active surveillance) and/or image-guided, minimally-invasive treatment, which can be performed in outpatient clinics with decreased complications, discomfort and costs; and
- Improved planning, administration and monitoring of individualized, precision treatment.

WHEN: With the appropriate public and private investment in research, precision prostate cancer diagnosis and treatment is expected to become widely available in 5 years.

HOW: AdMeTech Foundation's research program generates breakthrough results by creating “brain trusts”, integrating expertise and resources of the multi-disciplinary world leaders in science, medicine and industry.

Our education, awareness and advocacy campaign has resulted in the historic legislation in US Congress and the Massachusetts General Court, recognizing prostate cancer crisis as a public health priority and a leading health care disparity - and calling for increased public and private investment and partnerships.

PUBLIC RECOGNITION: AdMeTech received commendations from the Massachusetts Governor and General Court, Boston City Mayor, Boston City Council and other organizations. Our programs are supported by global leaders of medicine, industry, advocacy, government, sports and entertainment, U.S. Congress, professional organizations - and have been featured by major media, including the Associated Press, Boston Globe, Reuters, Wall Street Journal, Radio (e.g., NPR) & TV (e.g., ABC, CBS, NBC).

TAKE ACTION: Visit www.admetech.org to learn how you can make a difference, volunteer or donate.

CONTACT ADMETECH FOUNDATION: One Boston Place, Suite 2600, Boston, MA 02108; 617-523-3535 / @manogram
RESEARCH PROGRAMS

GOAL: To facilitate creation, testing and implementation of precision care for prostate cancer (PC), including screening, diagnosis and treatment by:

a. Improving prevention, early detection, prediction of progression, and staging;

b. Eliminating unnecessary biopsies & treatment;

c. Developing precisely-targeted biopsies and minimally invasive treatment for early disease; and

d. Improving clinical strategies for recurrent, oligometastatic and advanced disease.

BACKGROUND: Starting in 1998, AdMeTech’s research program, extensively supported by federal, state and private grants, has produced groundbreaking results and extensive scientific publications.

LANDMARKS (Selected)

- AdMeTech pioneered high-precision prostate MRI since 1998 by stimulating and supporting original research, clinical evaluation, global standardization of high quality service (PI-RADS) and large-scale implementation. Integration of this research with medical education and public awareness has been instrumental in clinical acceptance of MRI as a new standard of patient care. By 2014, prostate MRI was performed in over 500,000 American men, with over 20% annual increase since that time.
  - AdMeTech’s International Prostate MRI Working Group led the first statistically powered clinical trial of PI-RADS. This research showed nearly 5-fold improvement in early detection of aggressive PC and reduction of unnecessary treatment, paving the way for the NCI-supported multi-center trial.
  - Global PI-RADS standardization stimulated the interest of the American College of Radiology and European Society of Urogenital Radiology. This effort has led to a joint publication in the prestigious Journal of European Urology, winning its award as “The Best Research Paper” in 2017 and becoming one of the most cited research work.

- Since 2001, AdMeTech established the field of molecular imaging of PC and funded pioneering research at leading hospitals. For example, PET PSMA is currently among the most widely used and robust molecular imaging tools of PC today.


- Since 2016, AdMeTech’s Global Summit and Brain Trust on Precision Diagnosis & Treatment of PC became seminal in stimulating a multi-disciplinary, comprehensive approach to patient evaluation, integrating imaging with liquid biomarkers and genetic cancer profiling (radiogenomics) to ensure individualized care. This effort impacted clinical and research strategies, including VP Joe Biden’s Cancer Moonshot Program.

EDUCATION, AWARENESS AND ADVOCACY

GOAL: To expedite broad-based advancement of patient care, with the following aims:

a. Create new models of national and global leadership in prostate cancer research, education, awareness, advocacy and eliminating health disparities;

b. Expedite development and implementation of precision diagnostic tools, expected to transform screening, diagnosis and treatment;

c. Expand public/private investment and partnerships.

LANDMARKS (Selected, 2011 - now)

September 2011: The Massachusetts General Court supported AdMeTech-driven initiative to recognize prostate cancer as a public health priority, central issue in men’s health and major health care disparity.

July 2012: US Senate passed a bipartisan Prostate Cancer Resolution (S. 493), highlighting prostate cancer in African American men as a health care crisis and urging increased national investment in research for improved early detection (led by Senator John Kerry, D-MA).

June 27, 2012: Senator Barbara Boxer (D-CA) and Representative Elijah E. Cummings (D-MD) introduced the bipartisan Prostate Cancer Detection Research and Education Act to authorize $180M in federal funding to improve early detection of prostate cancer.

July 2013: Massachusetts Senate and House supported allocation of $1.5 million for the first statistically powered clinical trial of MRI and global PI-RADS. By August 2016, this retrospective trial, conducted in cooperation with Harvard Medical School, demonstrated a groundbreaking, near 5-fold impact of PI-RADS on improving early diagnosis of aggressive PC and reducing unnecessary treatment.

April 2014 - now: Groundbreaking coverage of the prostate cancer crisis and the importance of research, public awareness and education of accurate diagnostic tools by major media, including the Associated Press, Boston Globe, NBC, NECN TV, CBS, NPR and other major media.

September 2014 – 2015: Senator Barbara Boxer (D-CA) introduced AdMeTech-driven bi-partisan National Prostate Cancer Plan (NPCP) Act (S. 222) to develop and implement a national strategy for the advancement of diagnostic tools. The US House NPCP Act was introduced by US Reps GK Butterfield (D-NC), E. Cummings (D-MD), W. Jones (R-NC), and M. McCaul (R-TX).

July 2014 – now: Massachusetts Governor, Senate and House supported AdMeTech-led advocacy to create an annual program ($500,000 to $800,000 per year) in PC research, education and awareness, with priority focus on men with Black (including Hispanic and Latino) roots, family history and other high-risk individuals. This program’s unique focus on PC in general and high-risk men specifically created a Massachusetts model of national leadership.

March 2015 – now: Expansion of the Massachusetts program in PC research, education and awareness, with priority focus on high-risk men. This program has been featuring Massachusetts Governor Charlie Baker, CEO of Red Sox Larry Lucchino, Celtics great Cedric Maxwell, marathon icon Bill Rodgers, leaders of medicine, legislation, media and advocacy, including New England’s American Cancer Society Cancer Action Network and NAACP.